Nicotinamide riboside (NR) supplementation

The mechanism is real and the pharmacology is settled: oral NR reliably and dose-dependently raises blood NAD+ in humans, and it has a good short-term safety record across multiple placebo-controlled trials. What the evidence does NOT show is that raising NAD+ translates into any healthspan or longevity benefit. Human RCTs to date have largely failed to demonstrate consistent improvements in muscle function, insulin sensitivity, cardiovascular endpoints, cognition, or any ageing-relevant clinical outcome, and no trial has tested mortality or disease incidence. The impressive lifespan and healthspan results come from mice and cell models, not people. The only NR-specific study surfaced in this research round is a retrospective, non-randomised chart review of 14 patients (6 NAD+ IV, 8 NR IV) at a single US commercial wellness clinic, which found IV NR was much better tolerated than IV NAD+ (37 versus 97 minute infusions; minor tingling versus moderate-to-severe cramping, nausea and vomiting) with exploratory and variable metabolic signals. Its own authors call for adequately powered randomised placebo-controlled trials to determine effectiveness. That is a tolerability observation, not efficacy evidence. Graded "mechanism" rather than "clinical" because the human trial literature establishes a biomarker change (NAD+ elevation) without an accompanying healthspan outcome. NR is also routinely conflated with NMN in marketing; they are distinct molecules with distinct regulatory treatment, and evidence for one should not be read across to the other.

What it is

Plain-language explainer

Categories

Common questions

What is Nicotinamide riboside (NR) supplementation?

The mechanism is real and the pharmacology is settled: oral NR reliably and dose-dependently raises blood NAD+ in humans, and it has a good short-term safety record across multiple placebo-controlled trials. What the evidence does NOT show is that raising NAD+ translates into any healthspan or longevity benefit. Human RCTs to date have largely failed to demonstrate consistent improvements in muscle function, insulin sensitivity, cardiovascular endpoints, cognition, or any ageing-relevant clinical outcome, and no trial has tested mortality or disease incidence. The impressive lifespan and healthspan results come from mice and cell models, not people. The only NR-specific study surfaced in this research round is a retrospective, non-randomised chart review of 14 patients (6 NAD+ IV, 8 NR IV) at a single US commercial wellness clinic, which found IV NR was much better tolerated than IV NAD+ (37 versus 97 minute infusions; minor tingling versus moderate-to-severe cramping, nausea and vomiting) with exploratory and variable metabolic signals. Its own authors call for adequately powered randomised placebo-controlled trials to determine effectiveness. That is a tolerability observation, not efficacy evidence. Graded "mechanism" rather than "clinical" because the human trial literature establishes a biomarker change (NAD+ elevation) without an accompanying healthspan outcome. NR is also routinely conflated with NMN in marketing; they are distinct molecules with distinct regulatory treatment, and evidence for one should not be read across to the other.

How strong is the evidence for Nicotinamide riboside (NR) supplementation?

Mechanism only. The biological rationale is described, but human outcome data is not established.

Is Nicotinamide riboside (NR) supplementation approved in Singapore?

Health Sciences Authority position on record: Not a registered therapeutic product. In Singapore, NR would fall under HSA's health supplements framework, which involves no pre-market approval, licensing or registration: responsibility for safety, quality and compliance sits with the dealer, and voluntary notification is possible but not required. HSA publishes a maximum daily limit for nicotinamide (450 mg) but no NR-specific limit was found. Critically, health supplements in Singapore must not be labelled, advertised or promoted for any medicinal purpose, including claims implying treatment or prevention of disease or ageing-related conditions. No HSA-specific determination, ban, or safety alert naming nicotinamide riboside was located. Legally saleable as a supplement; not approved for any indication.. An evidence grade and a regulatory approval are different questions.

Is Nicotinamide riboside (NR) supplementation approved in Australia?

Therapeutic Goods Administration position on record: Not a registered (AUST R) prescription medicine for any indication. Nicotinamide riboside chloride IS a permissible ingredient for use in Australian listed medicines (AUST L), and the TGA has published a compositional guideline for it setting identity, purity and assay specifications. Listed products containing it exist on the ARTG (for example ARTG 419551 "Nicotinamide Riboside NR" and ARTG 450569 "Nicotinamide Riboside"). This matters because it distinguishes NR from NAD, NAD+ and NADH, which the TGA has stated are NOT permitted ingredients in listed medicines, and from NMN, which only became permissible on 10 December 2025 with a sponsor restriction until December 2027 and an oral-only route of administration. Listed-medicine status means low-level indications only (health maintenance/enhancement); it is NOT TGA approval for any anti-ageing or disease claim, and the TGA has not assessed NR for efficacy. Injectable/IV NR is not covered by this listing pathway. CAVEAT: TGA pages consistently blocked direct fetch during this research; this status is drawn from TGA-hosted pages surfaced via live search rather than from pages opened directly, and should be re-confirmed against the current Permissible Ingredients Determination before publication.. An evidence grade and a regulatory approval are different questions.

What else is Nicotinamide riboside (NR) supplementation called?

Also known as NR, Nicotinamide riboside chloride, Niagen, NAD+ precursor.